Dupont De Nemours, Inc. · NYSE:DD
Dupont De Nemours — Investor Day (September 2025)
81 slides from Dupont De Nemours's investor day presentation, Sep 18, 2025
Slide 1: Investor Day 2025
TM Investor Day 2025 Transform. Innovate. Accelerate. 2025 INVESTOR DAY 1
Slide 2: Welcome and Opening Remarks
Welcome and Opening Remarks Ann Giancristoforo Vice President, Investor Relations 2025 INVESTOR DAY 2
Slide 3: Forward looking statements
Forward looking statements On January 15, 2025, DuPont de Nemours, Inc. (“DuPont”, or after the completion of the Intended Electronics Separation, “New DuPont”) announced it is targeting November 1, 2025 to complete the intended separation of its Electronics business (the “Intended Electronics Separ
Slide 4: Basis of Presentation
Basis of Presentation Non-GAAP Financial Information: This presentation includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are considered non-GAAP measures. These non-GAAP financial measures supplement disclosures
Slide 5: Spin-off driving focus
Spin-off driving focus Healthcare & Water Diversified Semiconductor Interconnect Technologies Industrials Technologies Solutions Leading advanced solutions provider Premium pure-play technology solutions leader with a simplified portfolio highlighted by across the semiconductor value chain high-grow
Slide 6: Today's agenda
Today’s agenda 9:00 am Welcome and Opening Remarks Ann Giancristoforo | VP, Investor Relations The New DuPont Lori Koch | Chief Executive Officer Healthcare & Water Technologies Jeroen Bloemhard | President Diversified Industrials Beth Ferreira | President Financial Overview & Outlook Antonella Fran
Slide 7: The New DuPont
The New DuPont Lori Koch Chief Executive Officer 2025 INVESTOR DAY 7
Slide 8: Key messages
Key messages Executing Focused on Poised for Driving Enhancing transformation excellence growth disciplined culture to acceleration capital further enable allocation value creation Simplified portfolio, Continuing to drive A more focused, Unlocking Driving a increasingly focused innovation, agile or
Slide 9: Transforming to a simplified, more focused portfolio
Transforming to a simplified, more focused portfolio 2019 Portfolio 2025 Portfolio 2025 Pro Forma Portfolio Portfolio Actions Since 2021 Divested Mobility & Materials Acquired Spectrum & Donatelle Transportation Healthcare Healthcare Electronics Water Water Intended Food & Beverage Diversified Indus
Slide 10: The New DuPont
Industry expertise and Global scale The New DuPont differentiated technology with local presence Igniting change. Unlocking potential. Leading into the future. ~$6.9B ~5,100 Patents Leading Advanced 2025E Net Sales1 Solutions Provider ~$1.6B 2025E Operating ~13,000 EBITDA1 Colleagues ~23.6% Operatin
Slide 11: Compelling financial position as a multi-industrial company
Compelling financial position as a multi-industrial company DuPont Multi-Industrial Peer Average Net Sales Growth CAGR1 EBITDA Margin FCF Conversion2 EV/EBITDA Multiple FY19 – FY25E FY25E FY25E FY25E >90% 85% 16.7 25.7% 23.6% 2.4% 2.4% 11.4 77 Source: FactSet Market Data, Company Presentations. Peer
Slide 12: Activating change to maximize value
Activating change to maximize value From To Market Multiple areas More consolidated end market focus Focus of focus Differentially investing in areas of higher growth Organizational Centralized Decentralized lines of business segment leadership Enabling speed and accountability Culture Long-establis
Slide 13: Leading positions across attractive end markets
Leading positions across attractive end markets Healthcare Water Diversified Industrials Key • Medical Packaging • Industrial Water • Construction end-markets • Medical Devices • Municipal & Desalination • Automotive (including EV) • Protective Garments • Life Sciences & Specialty • Industrial/Aeros
Slide 14: Well positioned to capture growth
Well positioned to capture growth Healthcare Water Diversified Industrials Addressable Market1 $13B $7B $21B Market Growth1 GDP+ GDP+ GDP Megatrend Growth Single-Use Systems Freshwater Scarcity Electrification Drivers Occupational Growth of Water-Intensive U.S. Residential Safety Requirements Indust
Slide 15: Innovation excellence drives high-value solutions for customers
Innovation excellence drives high-value solutions for customers Dedicated R&D Focus Commitment to Differential Resource Innovation Excellence Allocation Model ~2.5% R&D Investment ~30% Prioritizing High-Growth Areas as a % of Net Sales New Product Vitality Index1 19 Global R&D and Leverage DuPont co
Slide 16: Clear focus on commercial excellence
Clear focus on commercial excellence Priority Actions Commercial Sales Strategic Pipeline Enablement Effectiveness Marketing Discipline • Optimize resource • Optimize route-to-market • Automate order entry Performance deployment • Expand addressable market • Deploy AI tools Management • Enhance lead
Slide 17: Building on a foundation of operational excellence
Building on a foundation of operational excellence Productivity Targets 2022 - 2025 2025-2026 2026 + Gross Foundation building Build out domain systems • Full integration of Productivity focus areas: focused on driving Lean and digital capabilities to • Process standardization Continuous Improvement
Slide 18: Building a business system to accelerate results
Building a business system to accelerate results System builds from foundational capabilities in innovation, operations & commercial excellence Innovation Commercial Evolving our managing processes Excellence Excellence to enhance visibility, rigor & speed G Driving performance with a Operational ho
Slide 19: Disciplined capital allocation
Disciplined capital allocation 1 2 3 4 5 Strong Balance Organic Growth Dividends Inorganic Share Sheet Investment Growth Repurchase <2x net ~2.5% R&D target Target 35 - 45% Focus on Return cash to leverage as a % of Net Sales payout ratio high growth shareholders verticals ~3% Business Capex1 target
Slide 20: Focused M&A strategy
Focused M&A strategy Strategic Filters Strategic Filters Focused on Adds key capabilities, Enhances our Healthcare and improves existing value proposition Water platforms capabilities to customers Financial Criteria Strategic Filters Organic growth Relatively low Low Ability to scale, ROIC > WACC ac
Slide 21: New perspectives to drive accelerated value creation
New perspectives to drive accelerated value creation 250+ years of combined experience across multiple leading companies Lori Koch Antonella Franzen Jeroen Bloemhard Beth Ferreira Chief Executive Officer Chief Financial Officer President, Healthcare President, Diversified Industrials 25+ YEARS 25+ Y
Slide 22: Confident in achieving medium-term targets
Confident in achieving medium-term targets Organic Growth 3 – 4% CAGR Driving innovation and capitalizing Organic Net Sales on long-term market tailwinds Margin Expansion 150 – 200bps Sustaining strong margins through continuous Improvement improvement and a high-growth asset mix Op. EBITDA Margin E
Slide 23: Clear strategy to drive value creation
Clear strategy to drive value creation Drive Operate top-tier businesses positioned Organic Growth in high-growth secular markets Rigorous commitment to further improving Build a Robust Business System commercial and operational excellence building off established foundation Enhance shareholder valu
Slide 24: Healthcare & Water Technologies: Business Overview
Healthcare & Water Technologies: Business Overview Jeroen Bloemhard President, Healthcare & Water Technologies 2025 INVESTOR DAY 24
Slide 25: Healthcare & Water Technologies: Key messages
Healthcare & Water Technologies: Key messages Attractive Innovation Positioned Markets Leadership to Win Favorable megatrends Differentiated Deep and collaborative in large secular technologies, application customer relationships markets driving expertise, and advanced with trusted reputation to lon
Slide 26: Healthcare & Water Technologies: At a glance
Healthcare & Water Technologies: At a glance ~$3.2B 2025E Net Sales 2025E Net Sales Healthcare Water ~30% 2025E Operating EBITDA Margin • Specialized materials and • Pure-play water technology product design solutions for provider with strong exposure high growth end-markets to secular growth driver
Slide 27: Healthcare Technologies
Healthcare Technologies 2025 INVESTOR DAY 27
Slide 28: Overview of Healthcare Technologies
Overview of Healthcare Technologies Key Metrics Brands Value Drivers Net Sales Mix ~$1.7B Strong position in fast-growing Geographic Split 2025E Net Sales healthcare markets with North America favorable megatrends EMEA 22 Broad set of best-in-class APAC Manufacturing healthcare solutions and offerin
Slide 29: Healthcare: Diverse capabilities to meet OEM needs
Healthcare: Diverse capabilities to meet OEM needs Categories Key Capabilities & Attributes Solving Customer Needs Medical Device CDMO1 • End-to-end design, prototyping & scale-up Co-develop life-saving • Advanced molding & precision extrusion medical devices; • Multi-material expertise manufacture
Slide 30: Favorable megatrends driving growth across key end markets
Favorable megatrends driving growth across key end markets Medical Device Biopharma Personal Protective CDMO1 & Packaging & Pharma Equipment Addressable $7B $3B $3B Market2 Key • Exposure to high-growth sub- • Penetration of single-use • Increased occupational Drivers segments, such as electrophysio
Slide 31: Healthcare Technologies: Driving strong, consistent growth
Healthcare Technologies: Driving strong, consistent growth Net Sales Financial Strength Growth Enablers ~5% Organic CAGR • Consistent, mid single- Broad range of advanced digit organic sales healthcare applications growth Next-gen medical device • Investing in development and differentiated technolo
Slide 32: Delivering customer requirements: Spectrum-enabled advanced heart catheters
Case Study Delivering customer requirements: Spectrum-enabled advanced heart catheters Customer need DuPont solution Value created Structural heart • Collaborated closely Increased revenue OEM urgently needed with customer to and profitability launch support for a navigate challenges Received award
Slide 33: Healthcare Technologies: Positioned to win
Healthcare Technologies: Positioned to win Industry expertise and Long-term and Global scale Trusted differentiated technology deep customer with local reputation relationships presence Best-in-class materials science Partnerships with top Footprint strategically Recognized leader capabilities, deli
Slide 34: Water Technologies
Water Technologies 2025 INVESTOR DAY 34
Slide 35: Overview of Water Technologies
Overview of Water Technologies Key Metrics Key Technologies Value Drivers Net Sales Mix ~$1.5B Industry-leading brands with Geographic Split 2025E Net Sales exceptional technology breadth North America and application development expertise EMEA 11 Reverse Osmosis APAC Differentiated multi-technology
Slide 36: Leading technology portfolio for water filtration needs
Leading technology portfolio for water filtration needs 60% of revenue is generated from customers buying more than one technology Membrane Aerated Biofilm Ultrafiltration (UF) Nanofiltration (NF) Reverse Osmosis (RO) Ion Exchange Reactors (MABR) & Filters particles, colloids, Removes large Removes
Slide 37: Favorable megatrends driving growth across key end markets
Favorable megatrends driving growth across key end markets Industrial Municipal Life Sciences & Emerging Water & Desalination Specialty Opportunities Addressable $3B $2B $2B Market1 Key • Strong global water • Increased regulations • 50% increase in food • Direct lithium Drivers demand from industri
Slide 38: Water Technologies: Driving strong, consistent growth
Water Technologies: Driving strong, consistent growth Net Sales Financial Strength Growth Enablers ~5% Organic CAGR • Consistent, mid single- Filtration and separation product digit organic sales growth performance leadership • Strong installed base Industry’s broadest filtration drives ~70% replace
Slide 39: Helping customers meet stringent water regulations: Fortilife Series
Case Study Helping customers meet stringent water regulations: Fortilife Series Customer need DuPont solution Value created Industrial customers • Decade-long RO innovation MLD installations can seek solutions to meet in membrane chemistry recover up to 95% of wastewater reuse and anti-fouling offer
Slide 40: Water Technologies: Positioned to win
Water Technologies: Positioned to win Industry expertise Long-term and Global scale Trusted and differentiated deep customer with local reputation technology relationships presence High-performance Global salesforce and Physical presence in 35 Category-leading product offering applications team with
Slide 41: Diversified Industrials Overview
Diversified Industrials Overview Beth Ferreira President, Diversified Industrials 2025 INVESTOR DAY 41
Slide 42: Diversified Industrials: Key messages
Diversified Industrials: Key messages Operate with Positioned Innovation Excellence to Win Leadership Expand margins Drive growth through Drive focused through rigorous global scale, deep innovation by application of customer relationships partnering with our operational excellence and market leadin
Slide 43: Diversified Industrials: At a glance
Diversified Industrials: At a glance ~$3.6B 2025E Net Sales 2025E Net Sales Building Industrial ~22% Technologies Technologies 2025E Operating EBITDA Margin • Leading portfolio serving both • Leading portfolio of adhesive, new-build and repair/remodel wear, and friction solutions that GDP applicatio
Slide 44: Diversified Industrials: Driving consistent performance
Diversified Industrials: Driving consistent performance Net Sales Financial Strength Performance Enablers ~2% Organic CAGR • Targeting organic sales Margin expansion growth in line with GDP through rigorous operational excellence • Continuous improvement for Increased use of competitive cost automat
Slide 45: Overview of Building Technologies
Overview of Building Technologies Key Metrics Leading Brands Value Drivers Net Sales Mix ~$1.6B Geographic Split Integrated systems drive builder 2025E Net Sales productivity, while ensuring North America energy-efficiency and protection 13 against the elements EMEA Manufacturing Robust portfolio of
Slide 46: Megatrends across key end markets
Megatrends across key end markets Non-Residential Residential Repair & Construction Construction Remodel Addressable $5B $4B $1B Market1 Key Ease of installation Drivers Cost efficiency and lean construction Housing supply gap Resiliency requirements Energy efficiency regulations Modern aesthetics a
Slide 47: Providing durability, safety and efficiency throughout the life of a structure
Providing durability, safety and efficiency throughout the life of a structure using building science Wall system Roof specific insulation design reduces risk to improve longevity of of mold growth the entire roof system Ultra hygienic, durable Continuous insulation and design flexibility for reduce
Slide 48: Combining speed and coverage with simplicity: Great Stuff Wide Spray
Case Study Combining speed and coverage with simplicity: Great Stuff Wide Spray Customer need DuPont solution Value created Insulation • Using iterative end-user Successful launch professionals want testing, lean innovation highlighted by 25,000 the speed and 3D-printed prototypes, units sold within
Slide 49: Overview of Industrial Technologies
Overview of Industrial Technologies Key Metrics Leading Brands Value Drivers Net Sales Mix ~$2.0B Leading provider of specified Geographic Split 2025E Net Sales innovative products and solutions designed to enhance North America performance and safety EMEA 26 APAC Local partner of choice for Manufac
Slide 50: Megatrends across key end markets
Megatrends across key end markets Automotive Other Industrials (including EV) (including Printing & Packaging and Aerospace) Addressable $5B $6B Market1 Key • Vehicle lightweighting • Automation and electrification Drivers • Electric vehicle builds set • ~30% of the world’s energy to exceed 40% of t
Slide 51: Strong foundation to win as electrification scales
Automotive (including EV) Strong foundation to win as electrification scales 2x 2x New DuPont DuPont content content DuPont Auto Adhesives in in EVs EVs vs vs ICE ICE DuPont Multibase® DuPont Tedlar® DuPont Molykote® DuPont Vespel® Lightweighting Increase Increase Optimize Ease of Improve Increase I
Slide 52: Continued focus on excellence drives value creation
Continued focus on excellence drives value creation Operational Excellence Innovation Excellence Commercial Excellence Disciplined application of Differentially invest in technology Active portfolio segmentation, framework to standardize best to address industry needs; application expertise, digital
Slide 53: High performance innovation at scale: Vespel Parts
Case Study High performance innovation at scale: Vespel® Parts Customer need DuPont solution Value created • Quick help in • Rapid prototyping and Collaborative solution development of testing for new components development at pace their new product • High performance polymer Lightweighting in high-
Slide 54: Diversified Industrials: Positioned to win
Diversified Industrials: Positioned to win Industry expertise Long-term and Global scale with Operating leverage and differentiated deep customer local presence through excellence technology relationships Multiple R&D 100, Edison Premium brand names Deep knowledge of local Decentralized organization
Slide 55: Financial Overview and Outlook
Financial Overview and Outlook Antonella Franzen SVP & Chief Financial Officer 2025 INVESTOR DAY 55
Slide 56: Key messages
Key messages Growth Consistent Robust Free Disciplined Maximizing Acceleration Execution Cash Flow Capital Long-Term and Margin Generation Allocation Value Expansion A streamlined A continued focus Strong earnings Maintaining a strong A strong financial portfolio focused on operational growth combin
Slide 57: Re-Casting FY 2025 Guidance: No Change to Underlying Guidance Assumptions
Re-Casting FY 2025 Guidance: No Change to Underlying Guidance Assumptions FY 2025 Net Sales Guidance FY 2025 Op. EBITDA Guidance ~$12.850B $(4.64)B ~$3.360B $(1.52)B $(1.35)B $(0.24)B ~$6.865B $1.590B $(15)M ~$1.575B Previous Electronics Aramids Current Previous Electronics Aramids Subtotal Disc Ops
Slide 58: 2025 Pro Forma financials
2025 Pro Forma financials FY 2025E Pro Forma FY 2025 FY 2025 Pro Forma Guide (Sep) Adjustments Pro Forma1 • Estimates New DuPont as a stand-alone for full 12 Net $6,865 – $6,865 months Sales • Adjustment relates to Op $1,575 $45 $1,620 right-sizing corporate costs EBITDA from $140M for Total DuPont
Slide 59: New DuPont: At a glance
New DuPont: At a glance Key Metrics Segment Net Sales Geographic Net Sales End Market Net Sales 4% 16% ~$6.9B 25% 24% 13% 47% 2025E Net Sales1 53% 51% 22% 21% 24% ~$1.6B Healthcare 2025E Operating Healthcare & North America Water EBITDA1 Water Technologies EMEA Construction Diversified Industrials A
Slide 60: Building on a foundation of strength
Building on a foundation of strength Compelling financial Strong balance A track record of profile positions us sheet supports consistent financial well for the future financial flexibility performance Increasing exposure to Ample liquidity Organic growth secular, high-growth end Balanced debt Margi
Slide 61: We have driven solid results while building momentum
We have driven solid results while building momentum Net Sales ($B) Operating EBITDA ($B) Operating EBITDA Margin 2.4% Organic CAGR 4.7% CAGR +200 BPS $6.9 23.6% $5.7 21.6% $1.6 $1.2 2019 2025E 2019 2025E 2019 2025E 2025 INVESTOR DAY Note: Operating EBITDA and Operating EBITDA margin metrics are pro
Slide 62: Strong history of shareholder returns
Strong history of shareholder returns >$14B Cumulative Cash Returned to Shareholders Total Shareholder Shares $14.4 Returns: Repurchased $13.8 $12.7 Dividends $10.0 $9.9B Paid Shares Repurchased $5.0 $4.5B $2.2 Dividends Paid $1.1 2H 20191 2020 2021 2022 2023 2024 2025E2 1 Gives effect to separation
Slide 63: Accelerating top line growth & margin expansion
Accelerating top line growth & margin expansion +3-4% Organic Sales CAGR $6.9B Net Sales Deployment of excess FCF +150 to 23.6% 200 bps is incremental to Op. EBITDA 2028 targets Margin Margin improvement $2.00 Adjusted 8-10% EPS EPS1 CAGR FY 2025E FY 2028E Pro Forma 2025 INVESTOR DAY 1 FY 2025E Adju
Slide 64: Favorable market trends driving growth
Favorable market trends driving growth FY25 – FY28E FY25 – FY28E Market Growth Organic CAGR ~5% Medical Device / Packaging Healthcare (25% of FY2025E Net Sales) Protective Garments Biopharma GDP+ Water Industrial Water & Energy (22% of FY2025E Net Sales) Municipal & Desalination Life Sciences & Spec
Slide 65: Operating margin improvement enhanced with productivity
Operating margin improvement enhanced with productivity +0-50bps Productivity >= Inflation +40bps Stranded Cost FY28E Reduction +150 to +110bps Leverage 200bps on Net Sales Op. EBITDA Growth Margin Expansion 23.6% ~1.7x Op. EBITDA Operating Margin Leverage FY25E Pro Forma 2025 INVESTOR DAY 65
Slide 66: Driving strong EPS growth
Driving strong EPS growth Up to +1% EPS CAGR from Cost Productivity +1% 8 to 10% Every 1% of Net Sales growth generates 2% EPS CAGR Adjusted EPS growth from Stranded Cost EPS CAGR Take-out over next 3 +7% years Adj. EPS CAGR (midpoint) from Net Sales Growth 2025 INVESTOR DAY 66
Slide 67: Strong free cash flow generation supporting further value creation
Strong free cash flow generation supporting further value creation Free Cash Flow Conversion1 Free Cash Flow • >90% conversion over the >90% medium term • Generating $2.7 - $2.8B in ~$2.7B - $2.8B cumulative cash Expect cumulative dividends of ~$1.2B2 >90% Expect cumulative share dilution of $12
Slide 68: Disciplined capital allocation
Disciplined capital allocation Organic Dividend Strategic Share Growth Payments Bolt-on M&A Repurchases 2025 INVESTOR DAY 68
Slide 69: Strong capital structure provides liquidity & financial flexibility
Strong capital structure provides liquidity & financial flexibility Summary Capitalization ($B) Credit rating of BBB+ Minimum Cash $1.0 Target Net Debt / EBITDA <2.0X Pro Forma Debt1 Significant liquidity ~$3.25 Maintain balance sheet flexibility to pursue organic and inorganic Revolving Credit Faci
Slide 70: Strong foundation to maximize long-term value creation
Strong foundation to maximize long-term value creation Operational Driving culture of operational excellence Execution to drive margin expansion Growth Operate top-tier businesses positioned in high-growth, Acceleration attractive end markets driven by secular demand trends and supported by proven i
Slide 71: Closing Remarks
Closing Remarks Lori Koch Chief Executive Officer 2025 INVESTOR DAY 71
Slide 72: Why invest in New DuPont?
Why invest in New DuPont? Leading advanced Simplified portfolio, Enhanced operating solutions provider, focused on higher framework, driving with differentiated growth, higher-margin excellence and technology end markets accelerating results Decentralized agile Clear path to 2028 Disciplined capital
Slide 73: Break
Break 2025 INVESTOR DAY 73
Slide 74: Q&A
Q&A 2025 INVESTOR DAY 74
Slide 75: Appendix
Appendix 2025 INVESTOR DAY 75
Slide 76: Re-Casting 3Q 2025 Guidance to exclude Aramids
Re-Casting 3Q 2025 Guidance to exclude Aramids: No Change to Underlying Guidance Assumptions 3Q 2025 Net Sales Guide 3Q 2025 Op. EBITDA Guide 3Q 2025 Adj. EPS Guide ~$3.320B $(0.34)B ~$875M ~$(65)M ($0.09) ~$1.15 ~$2.980B ~$810M $(5M) ~$1.06 ~$805M Previous Aramids Current 3Q25 Guide /Disc Ops 3Q25
Slide 77: Non-GAAP Financial Measures
Non-GAAP Financial Measures: Unless otherwise indicated, all financial metrics presented and discussion of results reflect continuing operations only. This communication includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP
Slide 78: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued): Organic Sales is defined as net sales excluding the impacts of currency and portfolio. Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash i
Slide 79: DuPont preliminary recast financial information
DuPont preliminary recast financial information For informational purposes only, the preliminary unaudited supplemental selected financial data and Non-GAAP financial measures presented on page 80 have been voluntarily provided to reflect the reclassification of the Aramids business and the Electron
Slide 80: Net Sales and Pro Forma Operating EBITDA calculation
DuPont de Nemours, Inc. Net Sales Twelve Months Ended December 31, 2024 ElectronicsCo DuPont As Aramids Discontinued Discontinued DuPont Recast Reported Operations In millions Operations Net Sales $ 12,386 $ 4,336 $ 1,332 $ 6,718 Selected Non-GAAP Calculation of Pro Forma Operating EBITDA (Unaudited
Slide 81: Trademarks notice
© 2025 DuPont de Nemours, Inc. All rights reserved. DuPont , the DuPont Oval Logo, and all products, unless otherwise noted, denoted with , ℠ or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.